Search results for "MUTATION"

showing 10 items of 2830 documents

Phosphorylated immunoreceptor tyrosine-based activation motifs and integrin cytoplasmic domains activate spleen tyrosine kinase via distinct mechanis…

2018

Spleen tyrosine kinase (Syk) is involved in cellular adhesion and also in the activation and development of hematopoietic cells. Syk activation induced by genomic rearrangement has been linked to certain T-cell lymphomas, and Syk inhibitors have been shown to prolong survival of patients with B-cell lineage malignancies. Syk is activated either by its interaction with a double-phosphorylated immunoreceptor tyrosine-based activation motif (pITAM), which induces rearrangements in the Syk structure, or by the phosphorylation of specific tyrosine residues. In addition to its immunoreceptor function, Syk is activated downstream of integrin pathways, and integrins bind to the same region in Syk a…

0301 basic medicinekinaasitCell signalingentsyymitIntegrinsintegrinIntegrinAmino Acid MotifsMutation MissenseSykPeptidechemical and pharmacologic phenomenaBiochemistryspleen tyrosine kinase (Syk)environment and public healthBiokemia solu- ja molekyylibiologia - Biochemistry cell and molecular biology03 medical and health sciencesProtein DomainsLääketieteen bioteknologia - Medical biotechnologyenzyme kineticshemic and lymphatic diseasescell signalingHumansSyk KinaseTyrosinePhosphorylationCell adhesionMolecular Biologychemistry.chemical_classificationsoluviestintäintegriinit030102 biochemistry & molecular biologybiologyChemistryta1182hemic and immune systemsCell Biology3. Good healthCell biologyEnzyme Activationenzymes and coenzymes (carbohydrates)030104 developmental biologyAmino Acid SubstitutionCytoplasmbiology.proteinPhosphorylationPeptidessurface plasmon resonance (SPR)Signal Transduction
researchProduct

A novel GABRB3 variant in Dravet syndrome: Case report and literature review

2020

Abstract Background Mutations in GABRB3 have been identified in subjects with different types of epilepsy and epileptic syndromes, including West syndrome (WS), Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), myoclonic‐atonic epilepsy (MAE), and others. Methods and results We herewith report on a girl affected by DS, who has been followed from infancy to the current age of 18 years. Next‐generation sequencing (NGS)‐based genetic testing for multigene analysis of neurodevelopmental disorders identified two likely de novo pathogenic mutations, a missense variant in GABRB3 gene (c.842 C>T; p.Thr281IIe) and a nonsense variant found in BBS4 gene (c.883 C>T; p.Arg295Ter). Conclusion A likely…

0301 basic medicinelcsh:QH426-470media_common.quotation_subjectNonsenseMutation MissenseEpilepsies Myoclonic030105 genetics & hereditymedicine.disease_causeClinical ReportsBBS4 gene03 medical and health sciencesEpilepsyDravet syndromeGeneticsMedicineMissense mutationHumansMolecular BiologyGeneGenetics (clinical)media_commonGenetic testingGeneticsMutationClinical Reportmedicine.diagnostic_testbusiness.industryGABRB3 GeneEpileptic EncephalopathiesWest Syndromemedicine.diseaseReceptors GABA-ADravet syndromelcsh:Genetics030104 developmental biologyPhenotypeCodon NonsenseChild PreschoolFemalebusinessMicrotubule-Associated Proteins
researchProduct

Strategies against nonsense: oxadiazoles as translational readthrough-inducing drugs (TRIDs)

2019

This review focuses on the use of oxadiazoles as translational readthrough-inducing drugs (TRIDs) to rescue the functional full-length protein expression in mendelian genetic diseases caused by nonsense mutations. These mutations in specific genes generate premature termination codons (PTCs) responsible for the translation of truncated proteins. After a brief introduction on nonsense mutations and their pathological effects, the features of various classes of TRIDs will be described discussing differences or similarities in their mechanisms of action. Strategies to correct the PTCs will be presented, particularly focusing on a new class of Ataluren-like oxadiazole derivatives in comparison …

0301 basic medicinemedia_common.quotation_subjectNonsenseNonsense mutationRegulatorSettore BIO/11 - Biologia MolecolareReviewComputational biologyBiologyOxadiazoleCatalysiscystic fibrosislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicineAtalurenTranslational readthrough inducing drugsPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyGeneSpectroscopymedia_commonNonsense mutationOrganic ChemistryTranslational readthroughoxadiazolesPremature termination codonTranslation (biology)General MedicineSettore CHIM/06 - Chimica OrganicaSmall moleculeSettore CHIM/08 - Chimica FarmaceuticaTransmembrane proteinComputer Science ApplicationsSettore BIO/18 - Genetica030104 developmental biologyPharmaceutical Preparationslcsh:Biology (General)lcsh:QD1-999Codon NonsenseProtein Biosynthesis030220 oncology & carcinogenesisCystic fibrosi
researchProduct

Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand.

2018

Wnt signaling is important for proper embryonic development, shaping cell fate and migration, stem cell renewal, and organ and tissue formation. Here, Luther et al. investigated the role of Wnt1 in osteoporosis. Patients with early-onset osteoporosis and with WNT1 mutations had low bone turnover and high fracture rates, and loss of Wnt1 activity caused fracture and osteoporosis in mice. Inducing Wnt1 in bone-forming cells increased bone mass in aged mice, and this process did not require Lrp5, a co-receptor involved in Wnt signaling. This study identifies Wnt1 as an anabolic (bone building) factor and suggests that it might be a therapeutic target for osteoporosis.WNT1 mutations in humans a…

0301 basic medicinemedicine.medical_specialtyAginganimal structuresAnabolismCellular differentiationOsteoporosis030209 endocrinology & metabolismMice TransgenicWnt1 ProteinLigandsBone and BonesBone remodeling03 medical and health sciencesFractures Bone0302 clinical medicineAnabolic AgentsOsteogenesisInternal medicineCortical BoneMedicineAnimalsHumansTransgenesOsteoblastsbusiness.industryIncidenceWnt signaling pathwayLRP5OsteoblastCell DifferentiationGeneral MedicineOrgan Sizemedicine.disease030104 developmental biologyEndocrinologymedicine.anatomical_structureLow Density Lipoprotein Receptor-Related Protein-5Osteogenesis imperfectaembryonic structuresMutationBone RemodelingbusinessScience translational medicine
researchProduct

Oxidative stress biomarkers in Fabry disease: is there a room for them?

2020

Abstract Background Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by deficient activity of the alpha-galactosidase A enzyme leading to progressive and multisystemic accumulation of globotriaosylceramide. Recent data point toward oxidative stress signalling which could play an important role in both pathophysiology and disease progression. Methods We have examined oxidative stress biomarkers [Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), thiolic groups] in blood samples from 60 patients and 77 healthy controls. Results AOPP levels were higher in patients than in controls (p < 0.00001) and patients presented decreased levels of…

0301 basic medicinemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentGlobotriaosylceramideOxidative phosphorylationDiseasemedicine.disease_cause03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelysoGb3Internal medicinemedicineHumansFabry diseaseOriginal Communicationbusiness.industryBiomarkermedicine.diseaseFabry diseasePathophysiologyOxidative Stress030104 developmental biologyEndocrinologyNeurologychemistryAdvanced oxidation protein productsalpha-GalactosidaseMutationNeurology (clinical)businessBiomarkers030217 neurology & neurosurgeryOxidative stressJournal of Neurology
researchProduct

Development of artemisinin resistance in malaria therapy

2019

Malaria affects 200 million people worldwide. Today, the most successful treatments are artemisinin-based combination therapies (ACT). Resistance has already been described for the elder anti-malarials chloroquine, sulfadoxine-pyrimethamine and mefloquine. Unfortunately, over the last few years there has also been an emerging resistance to the successfully used drug artemisinin, especially in African and Asian countries. A systematic PubMed literature research was conducted for studies published between January 2002 and December 2018. Despite ACTs continue to be first line treatment, the number of studies is rising reporting on artemisinin resistance mutations. Most publications reported on…

0301 basic medicinemedicine.medical_specialtyDrug ResistanceAntimalarials03 medical and health sciences0302 clinical medicineChloroquineparasitic diseasesAsian countryAnimalsHumansMedicineArtemisininIntensive care medicinePharmacologyPolymorphism Geneticbusiness.industryMefloquineArtemisinin resistancemedicine.diseaseArtemisininsTreatment efficacyMalariaFirst line treatment030104 developmental biology030220 oncology & carcinogenesisMutationbusinessMalariamedicine.drugPharmacological Research
researchProduct

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

WES/WGS Reporting of Mutations from Cardiovascular "Actionable" Genes in Clinical Practice: A Key Role for UMD Knowledgebases in the Era of Big Datab…

2016

International audience; High-throughput next-generation sequencing such as whole-exome and whole-genome sequencing are being rapidly integrated into clinical practice. The use of these techniques leads to the identification of secondary variants for which decisions about the reporting or not to the patient need to be made. The American College of Medical Genetics and Genomics recently published recommendations for the reporting of these variants in clinical practice for 56 "actionable" genes. Among these, seven are involved in Marfan Syndrome And Related Disorders (MSARD) resulting from mutations of the FBN1, TGFBR1 and 2, ACTA2, SMAD3, MYH11 and MYLK genes. Here, we show that mutations col…

0301 basic medicinemedicine.medical_specialtyKnowledge BasesGenomicsmarfan-syndrome[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics030105 genetics & heredityBiologycomputer.software_genreGenomeExAC03 medical and health sciencesAnnotationincidental findingsGeneticsmedicineHumanspathogenicityGenetic Predisposition to Diseasetgfbr2ExomegenomeESPGenetics (clinical)Exome sequencing[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM]variantsDatabasethoracic aortic-aneurysmsGenome HumanHigh-Throughput Nucleotide SequencingMYLKGenomicspredictionmutations3. Good healthMarfan syndrome030104 developmental biologydissection[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsCardiovascular DiseasesMutationMedical geneticsIdentification (biology)LSDB[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]computerexome
researchProduct

Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine

2019

Abstract Background The identification of biomarkers to drive treatment is one of the most important objectives of precision medicine. During last years, the role of PIK3CA mutations have been related to clinical benefit deriving from treatment with PI3K, and mTOR inhibitors. In breast cancer (BC), PIK3CA mutations are widely present and the use, in clinical trials, of selective inhibitors improved clinical outcomes. The aim of this study is to assess the value of a monocentric genomic screening program to select patients for trials with experimental targeted agents. Methods We examined PIK3CA mutation in a cohort of 312 metastatic BC patients diagnosed at Hospital Clinico Valencia-INCLIVA …

0301 basic medicinemedicine.medical_specialtybusiness.industryHematologymedicine.diseaseDiscovery and development of mTOR inhibitorsPrecision medicineGenomic screeningClinical trialMutational analysis03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicineCohortmedicinebusinessTriple negativeAnnals of Oncology
researchProduct

High HFE mutation incidence in idiopathic erythrocytosis.

2018

0301 basic medicinemedicine.medical_specialtybusiness.industryIncidence (epidemiology)IncidenceHematologyPolycythemiaGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicineMutation (genetic algorithm)MutationmedicineHumansIdiopathic erythrocytosisbusinessHemochromatosis ProteinBritish journal of haematology
researchProduct